ImmunityBio Inc IBRX

NAS: IBRX | ISIN: US45256X1037   2/04/2026
7,300 USD (+2,24%)
(+2,24%)   2/04/2026

4 april 2026 · INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit · Persbericht

1 april 2026 · ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman · Persbericht

30 maart 2026 · ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman · Persbericht

29 maart 2026 · IBRX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 · Persbericht

9 maart 2026 · ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data · Persbericht

17 februari 2026 · New Treatment Modalities Are Reaching Cancers That Resisted Everything Else · Persbericht

17 februari 2026 · New Treatment Modalities Are Reaching Cancers That Resisted Everything Else · Persbericht

16 september 2025 · Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals · Persbericht

12 juni 2025 · As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry · Persbericht

8 april 2025 · Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities · Persbericht

5 juli 2023 · Calling All ImmunityBio, Inc. (IBRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC Today! · Persbericht

Mijn selecties